BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 32286841)

  • 1. Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for
    Kelly JM; Ponnala S; Amor-Coarasa A; Zia NA; Nikolopoulou A; Williams C; Schlyer DJ; DiMagno SG; Donnelly PS; Babich JW
    Mol Pharm; 2020 Jun; 17(6):1954-1962. PubMed ID: 32286841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
    Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
    J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
    Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
    J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.
    Kelly J; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; Schlyer D; Zhao Y; Kim D; Babich JW
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1841-1851. PubMed ID: 29623376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
    Nedrow JR; Latoche JD; Day KE; Modi J; Ganguly T; Zeng D; Kurland BF; Berkman CE; Anderson CJ
    Mol Imaging Biol; 2016 Jun; 18(3):402-10. PubMed ID: 26552656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
    J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
    Kelly JM; Amor-Coarasa A; Nikolopoulou A; Wüstemann T; Barelli P; Kim D; Williams C; Zheng X; Bi C; Hu B; Warren JD; Hage DS; DiMagno SG; Babich JW
    J Nucl Med; 2017 Sep; 58(9):1442-1449. PubMed ID: 28450562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
    Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
    Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.
    Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H
    Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for
    Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C
    Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
    Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F
    Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
    Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
    J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Trifunctional Theranostic Ligand Targeting Fibroblast Activation Protein-α (FAPα).
    Kelly JM; Jeitner TM; Ponnala S; Williams C; Nikolopoulou A; DiMagno SG; Babich JW
    Mol Imaging Biol; 2021 Oct; 23(5):686-696. PubMed ID: 33721173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
    Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
    Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing Treatment Efficacy of
    Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
    Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
    J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of [
    Cui C; Hanyu M; Hatori A; Zhang Y; Xie L; Ohya T; Fukada M; Suzuki H; Nagatsu K; Jiang C; Luo R; Shao G; Zhang M; Wang F
    Am J Nucl Med Mol Imaging; 2017; 7(2):40-52. PubMed ID: 28533936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.